• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Bentley Pharmaceuticals Named One of Forbes 200 Best Small Companies

Posted on: Tuesday, 18 October 2005, 12:00 CDT

Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that it has been ranked number 76 by Forbes as one of America's 200 Best Small Companies.

The Forbes list includes companies with annual revenues between $5 million and $750 million, net profit margins exceeding 5%, and a fair market value above $5 per share as of September 29, 2005. Financial institutions, REITs and utilities are excluded from the list. The companies included on the list are ranked not only on the current and historical financial performance, but also on other non-financial indicators including, but not limited to corporate governance, Board of Director membership and Executive and Director compensation relative to applicable stock index. The Los Angeles firm of William O'Neil & Company provided Forbes with its accounting services in assessing these qualifications.

John A. Sedor, president of Bentley, said, "We are very pleased with this recognition by Forbes. What is particularly gratifying is the fact that the Forbes ranking combines our financial results and growth over the past five years with certain non-financial objective criteria. Inclusion in this listing is a tribute to the hard work and dedication of all of Bentley's employees in recent years."

Mr. Sedor added, "Coming on the heels of a FORTUNE magazine listing as one of America's 100 Fastest- Growing Companies, we are honored to be included in this list as well. We look forward to realizing our goals of continued expansion in Europe through our pending product approvals and license agreements and the execution of our expansion plan for the US which includes the introduction of our generic products into the US marketplace and the discovery and implementation of new drug delivery technologies."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding the growth of our business. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the timing and nature of regulatory approvals, expanding generic and branded drug operations, changes in third party reimbursement and government mandates which impact pharmaceutical pricing, development and commercialization of our proprietary products and formulations, competition from other manufacturers of generic and proprietary pharmaceuticals, intellectual property litigation, our relationships with our strategic partners, the efficacy and safety of our products, the unpredictability of patent protection, the effects of economic conditions, risks associated with international operations, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

Source: Business Wire

More News in this Category